Natera (NTRA) Jefferies Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Jefferies Global Healthcare Conference summary
18 Nov, 2026Quarter and leadership
Revenue grew 42% YoY ex-true-ups; Signatera posted another record growth quarter, with sequential ASP gains and strong organic gross margin performance.
Full-year revenue guidance was reset to above $3B; Signatera was described as addressing an estimated $20B annual opportunity, with roughly $1B penetrated to date.
CEO Steve is stepping down after eight years in the role; Solomon Moshkevich, a long-tenured leader across women’s health, Prospera and oncology, is taking over in a warm handoff.
Revenue target and Signatera growth
The $6B-plus 2029 revenue target assumes continued execution, including modest growth in women’s health and organ health and Signatera patient growth broadly in line with the rolling four-quarter average of quarterly unit growth.
Signatera’s 2029 ASP target is $1,450 versus roughly $1,290 currently; nine MolDX coverage applications are in flight, and broader tumor coverage could add $200–$300 to ASP.
MolDX responses typically take 9–12 months; further ASP opportunities include Medicare Advantage reimbursement compliance, commercial coverage in biomarker states and possible NCCN guideline adoption in colorectal and breast cancer.
New patient starts were described as strong and increasing; they represent roughly 10%–15% of quarterly clinical MRD volume, while existing-patient retention and tests per patient are expected to follow established patterns.
Signatera Genome roadmap
Signatera Genome expands baseline sequencing from the exome to the whole genome, enabling a broader set of personalized targets; phased and structural variants are intended to improve sensitivity without meaningful additional false positives.
Outcomes trials are expected to read out in 2027 and 2028, with samples also analyzed using the newer assay; the resulting evidence may accelerate demand for Signatera Genome.
Genome-backbone test COGS are currently higher than exome COGS; temporary cost increases are expected to last a couple of quarters, while phased variants add little cost.
Latest events from Natera
- A $6B 2029 target builds on Signatera growth, with screening and Japan extending the runway.NTRA
UBS Global Healthcare Conference - A $6B 2029 target and expanding cancer-testing opportunity frame the outlook.NTRA
8th Annual Wolfe Research Healthcare Conference - Revenue grew 34% as volumes climbed, lifting FY2026 guidance and supporting a $6B 2029 target.NTRA
Q3 2026 - Record growth, expanding global reach, and innovation drive strong financial and operational results.NTRA
2026 Global Healthcare Conference - Record MRD growth, expanding biopharma ties, and innovation set the stage for sustained expansion.NTRA
Morgan Stanley 24th Annual Global Healthcare Conference - Record Q2 growth, product innovation, and global expansion drive strong outlook.NTRA
Canaccord Genuity's 46th Annual Growth Conference - Revenue up 38% to $753M, record test volumes, improved margins, and raised guidance.NTRA
Q2 2026 - Record growth, innovation, and AI-driven strategies are accelerating adoption and market expansion.NTRA
Morgan Stanley 23rd Annual Global Healthcare Conference - Record growth, innovation, and clinical momentum set the stage for major milestones in 2025.NTRA
43rd Annual J.P. Morgan Healthcare Conference 2025